|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cerevel Therapeutics Holdings, Inc. (CERE) |
|
|
$44.63 0.00 (0.00%) as of 4:30 Tue 7/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
156,320,000 |
| Market
Cap: |
6.98(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$40.31 - $44.96 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 402 |
| Guru Rank Value : 5.7 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
17,422,701 |
| Total Buy Value |
$0 |
$0 |
$0 |
$397,510,553 |
| Total People Bought |
0 |
0 |
0 |
6 |
| Total Buy Transactions |
0 |
0 |
0 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
684,132 |
| Total Sell Value |
$0 |
$0 |
$0 |
$24,476,387 |
| Total People Sold |
0 |
0 |
0 |
8 |
| Total Sell Transactions |
0 |
0 |
0 |
28 |
| End Date |
2025-04-10 |
2025-01-07 |
2024-07-09 |
2023-07-10 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bain Capital Partners Xii, Llc |
|
– • • |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(65,679,781) |
0 |
|
- |
|
| Mckernan Ruth |
|
– • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,743) |
0 |
|
- |
|
| Renger John |
Chief Scientific Officer |
• – – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,370) |
0 |
|
- |
|
| Pfizer Inc |
Former 10% Owner |
– – – |
2024-08-01 |
4 |
D |
$45.00 |
$1,230,714,495 |
D/D |
(27,349,211) |
0 |
|
- |
|
| Akamine Scott |
Chief Legal Officer |
• – – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,527) |
0 |
|
- |
|
| Sanchez Ramiro |
Chief Medical Officer |
• – – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,673) |
0 |
|
- |
|
| Giordano Douglas E. |
|
– • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,743) |
0 |
|
- |
|
| Tregoning Kathleen |
See Remarks |
• – – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(10,666) |
0 |
|
- |
|
| Dipietro Kenneth |
Chief Human Resources Officer |
• – – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,042) |
0 |
|
- |
|
| Patrick Deval L |
|
– • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,743) |
0 |
|
- |
|
| Renaud Ronald C Jr |
President & CEO |
• • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(83,857) |
0 |
|
- |
|
| Renaud Ronald C Jr |
President & CEO |
• • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(160,452) |
0 |
|
- |
|
| Coles N Anthony |
|
– • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(25,928) |
0 |
|
- |
|
| Bodenrader Mark |
See Remarks |
• – – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(17,724) |
0 |
|
- |
|
| Greene Gabrielle E |
|
– • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(58,876) |
0 |
|
- |
|
| Altschuller Susan |
Chief Financial Officer |
• – – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,913) |
0 |
|
- |
|
| Koppel Adam |
|
– • • |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(65,679,781) |
0 |
|
- |
|
| Koppel Adam |
|
– • • |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,743) |
0 |
|
- |
|
| Burgess Paul D. |
See Remarks |
• – – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(45,727) |
0 |
|
- |
|
| Dekkers Marijn E |
|
– • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(402,326) |
0 |
|
- |
|
| Dekkers Marijn E |
|
– • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(42,283) |
0 |
|
- |
|
| Gordon Christopher R |
|
– • • |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(65,679,781) |
0 |
|
- |
|
| Gordon Christopher R |
|
– • • |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,743) |
0 |
|
- |
|
| Riedel Norbert G |
|
– • – |
2024-08-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(56,553) |
0 |
|
- |
|
| Coles N Anthony |
|
– • – |
2024-07-01 |
4 |
AS |
$41.18 |
$1,029,535 |
D/D |
(25,000) |
25,928 |
|
-100% |
|
220 Records found
|
|
Page 1 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
